# 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC

Source: https://onco.cc/trials/nct07043270/  
OnCo record `nct07043270` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of gemcitabine + nab-paclitaxel and fOLFIRINOX / mFOLFIRINOX in pancreatic cancer, run by Dartmouth-Hitchcock Medical Center, now recruiting.

## Summary

24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC is a phase 2, interventional study registered as NCT07043270 by Dartmouth-Hitchcock Medical Center, with a registry enrolment figure of 35 participants, started 2025-09-29 and due to reach its primary completion in 2028-07-01. Interventions recorded: Nab-paclitaxel + Gemcitabine; modified FOLFIRINOX (mFOLFIRINOX). Conditions listed: Pancreas Adenocarcinoma. Primary outcome: One-year event-free survival (1y-EFS). Pancreatic eligibility wording from the registry: "2024 Pancreatic Adenocarcinoma". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07043270
- Phase: 2
- Setting: 24BRO681 : Neoadjuvant Therapy With Alternating Gemcitabine Plus Nab-Paclitaxel and mFOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial
- Sponsor: Dartmouth-Hitchcock Medical Center
- Enrolled: 35

## Sources

- ClinicalTrials.gov NCT07043270: https://clinicaltrials.gov/study/NCT07043270

## Connected records

- cancers: [Borderline resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/borderline-resectable-pdac/), [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [FOLFIRINOX / mFOLFIRINOX](https://onco.cc/drugs/folfirinox/), [Gemcitabine + nab-paclitaxel](https://onco.cc/drugs/gemcitabine-nab-paclitaxel/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07043270.json